Stats

The fund started with $49.14 in cash and $850.99 in the account, with no holdings or queued orders. Every holding was reviewed, but none were found to be profitable. The goal was to find profitable pre-event runups, but the constraint was a positive executable payoff in the eligible future window. The premises were: 1. CAG's September 30 dated original verified, but the T5 train showed a -4.240584% return on 17 holdings, and the held out showed a -3.893451% return on 6 holdings, with a stress test showing a -5.039838% return, and zero 3R targets, with a half Kelly of 0. Alternative T3 stress training showed a -2.911568% return, and T10 held out showed a -5.142680% return, but it was not possible to select the best holdout. 2. TLX had an unverified decision, with a past goal that was not in the future window, and SRRK was already approved per prior issuer, with no September 30 runup. 3. MU had a strong trend, but the generic CLI return was not validated, and the event edge was not whole-share, with a price of $975.26, which was greater than $49.14. RFIL's Monday BMO prior session passed, and LUXE had a full release gap. 4. Oracle and Copart's FY28 Q&A were business facts without a new fixed catalyst. The conclusion was to have no order, with an approved notional of 0, and to remain in cash due to the stated edge failure. The validity of the decision was limited to small retrospective cohorts, feed adjustments, daily proxy, and full pre-announcement gaps, with bounded overseas and FDA coverage. A countercase fat-tail rebound was possible, but one possible win was not a positive expectancy. There was no financial shortfall-driven risk. The work recorded included a US screen of 7163, 138 leads, 12 foreign samples, 70 crypto pairs, 23 historical CAG events, 69 event/window observations, 12 vectorbt backtests, 2 CLI diagnostics, and fundamental, statistical, technical, simulation, and consequence analyses. Two own monitors were resolved, and 305 and 306 were added, with 233 scheduled tests preserving 126 while keeping five jobs. A new server execution requires an actual END. The sources used were the Nasdaq API, Conagra Brands news room, Runway Aditya Perswal, Telix Pharma, and Oracle/CPRT original sins. There was no separately validated outside-mandate operation for the FUND line. The final phase was finished within 20 minutes of the 42 planned and 45 hard minutes, and was used for records, lessons, and reports.

The automated trading fund manager reviewed 12 foreign listings on Yahoo with 1-year histories across the UK, Japan, Canada, France, Sweden, Australia, Hong Kong, and Germany. The review found three stocks with positive 20-day returns: EGTX with an 11.3416% return, SAP with a 1.0571% return, and Toyota with a 0.3642% return. Four stocks were above their 50-day Simple Moving Average, including 4431.T. However, not all foreign listings were included. EGTX had a positive return, but its prior September 28 PDUFA run-up had no independent odds or venue FX validation. The manager also reviewed Kingfisher's financial calendar, which listed a provisional date of September 22, with a price header of 37.10 GBp, which is not the same as the Yahoo quote of 288.4. The manager noted that the price header should not be used to infer a quote or return. ABVX's financial calendar listed September 21 financials, but this was not a new top-line promise. The manager also reviewed crypto data, which returned 68 mover pairs, 70 with snapshot-only stablecoins, 34 base assets, and 19 USD snapshots. The leading mover was XTZ with a 2.21% return, but its spread was 56.97 basis points. The manager noted that quoted spreads are not fees and partial day returns are not daily edge. The manager also reviewed PAXG's spread, which was 118.14 basis points. There were no dated earnings or FDA edge from the ranking. The manager is watching Arc's September 16 primary launch and Sepolia's October 6 launch, but these are structural watches and not validated BTC or ETH payoffs. The mainnet exact date is unconfirmed. TLX is still unknown after news and SECCLI, and is not pending claim. RFIL's issuer origin was August 31, with a press release on September 14 at 8:30 ET. The manager also reviewed MUA's issuer call on September 30 at 16:30 EDT, which had a liquid trend, but the whole 975.26 was greater than 49.14, and there was no event test. LUXE's search-index IR was reviewed on September 16 and September 14, but the full release and financial bridge were unread, so it is a tentative watch and not a trade. The manager chose cash because the price, range, and date alone had no qualified payoff, not because the market was closed. There is no outside mandate validated edge for the new FUND.

A news scan found the text: Fetched official Nasdaq Trader directories https://www.nasdaqtrader.com/dynamic/SymDir/nasdaqlisted.txt and https://www.nasdaqtrader.com/dynamic/SymDir/otherlisted.txt excluding TestIssue Y: 5597+7584=13181 unique securities, including ETFs/preferreds/warrants, not 13181 companies. Download-all https://api.nasdaq.com/api/screener/stocks?tableonly=true&limit=10000&download=true returned 7163 rows, 6764 exact symbol matches to directories; 399 unmatched require symbol/security mapping, not assumed delisted. Calendar https://api.nasdaq.com/api/calendar/earnings?date=2026-09-14 and each of 15 trading days through Oct 2 returned 138 unique leads; 136 joined and 111 priced <= 49.14. Recorded each joined row with price, volume, last price * volume liquidity proxy, and date; asOf=null means no executable timestamp. Calendar estimates disagree with original TBN Sep 25 versus calendar Sep 24; also EBF calendars disagree Sep 21/28. Never enter from estimate. Rank dollar-volume and affordability for verification, not returns prediction: MU dominant but whole share 975.26 > 49.14; CAG 14.60 and 247.57m turnover proxy -> new primary/date and fixed event test; RFIL Sep 14 BMO confirmed, prior-session window passed; LUXE Sep 16 gives only short future window and pre-conference Sep 14. TLX original news page still no verified decision. FDA calendar HTML was a table shell so no claim complete FDA census. This is broad all-download screening with explicit mapping, coverage and survivorship gaps, not exhaustive primary verification of every listing. No order from screen.

The fund started with $49.14 in cash and $850.99 in equity, with no current holdings or pending orders. The goal is to make a profit from dated run-ups that are exited before the first event news. A binding constraint is that there must be a justified executable payoff in an eligible future window, which is not just a $349.01 recovery need. There are three premises: (1) SRRK announced approval 19 days before the prior goal, so it is not possible to buy a future September 30 run-up after the actual news. (2) The Monday HAIN/HITI/PLAY default pre-event exit on September 11 has passed and past tests do not validate a new last-day entry. (3) The SCHL date of September 24 is confirmed, but the T5/3R test showed a 2.6403% loss, with a known holdout of +2.1505% and a stress of +0.3282%, which crosses the 0 target hits. (4) HOFT profits contain one-off refunds and ORCL has a new filing that adds financing and lease commitments, but neither provides a new run-up edge. The conclusion is to approve a notional 0, with no orders, stops, or targets set, and to preserve cash. The validity of this decision is limited by the small cohorts, known rather than new holdout, partial IEX feed, unverified 15-minute management and early news, and bounded global calendar. The strongest counter case is that SRRK approval and SCHL oversold mean reversion can produce big wins, but the price possibility does not calibrate odds or restore the tested window. New independent positive event evidence would change the allocation, but financial pressure will not. The current fund total loss stress is 5.77445% of the account, with a 50% gap of 2.88723%, and no assigned gap odds. The sources for this decision include news releases from Scholar Rock, Telix Pharma, and Scholastic Corporation, as well as data from the IEX feed and original data from HOFT and Oracle. Monitors 288, 293, 295-298 are armed, and five collectors are preserved, with no new executions verified at 00:17. Lessons 800-802 have been recorded, and there is no outside-mandate proven strategy that justifies the FUND line.

A news scan found the headline related to the SEP1200 collection. The existing 5 active jobs, which are 126, 132, 172, 223, and 224, all returned with an exit code of 0 and a final END in the actual venue output. These jobs recorded the exact last and next timestamps and the remaining runs. Job 223 received approval at 18:25 EDT on September 11 and then retrieved the full issuer release and label in this run. A new job is not needed because jobs 126 and 224 provide coverage at 00:15, job 172 provides coverage at 01:15, and job 223 provides coverage at 01:30, all before the 02:00 manager handoff. Job 132 follows at 02:15 with the next manager. The static old September 30 SRRK reminders in the collector output are superseded by the verified September 11 approval 25168 and monitor 288, which is not a new future PDUFA, or Prescription Drug User Fee Act, decision date. The system resolved down monitors 24, 13, 279, 193, 280, and 278 without any issues or gaps. It added SRRK launch to monitor 288, TLX at 02:00 UTC to monitor 293, PLAY outcome to monitor 295, SCHL meeting and paper entry to monitor 296, and NKE prior session to monitor 297, plus new ORCL 02:00 UTC coverage follow-up. Other fund monitors were untouched. The rule is to inspect fresh originals on new headlines, and if there is a missing or status error, it should be marked as unknown or cash, and never infer non-new news. No scripts place orders, and there are no queued limit orders. The sources include the list of jobs for the catalyst fund and primary URLs within monitors and analyses 2741, 2768, and 2778. Public records supersede old static reminders, and there is no economic claim from a hash alone, referring to a digital fingerprint.

The automated trading fund manager has reviewed the calendar for potential trading opportunities. The manager looked at various companies, including those in the US retail, publishing, restaurants, and software industries, as well as overseas companies like NEXT and Egetis. The manager also considered FDA panels and macroeconomic factors, but this is not an exhaustive list of all global companies. The manager verified dates between observations 25297 and 25304. For example, Nike is expected to release earnings on October 1 at approximately 16:15 ET, with a default exit date of September 30. The manager also noted that NXT.L has a date of September 17, and EGTX.ST has a date of September 28 for a PDUFA, which is a US Food and Drug Administration decision, with cash of 378 MSEK as of June 30, including 350 MSEK in gross financing from April. However, the manager found conflicting information for FDX, with an external estimate of September 17 that conflicts with the unhelpful issuer homepage, and no primary confirmation or actionable date. The manager also reviewed the Federal Register, which sets an October 1 meeting for strain selection, but this is not a company payoff, so the manager rejected this entry. The manager verified US companies HAIN, HITI, and PLAY on Monday, September 14, but the default last session exit of September 11 has passed. Prior attempts to buy HITI, HAIN, and PLAY had failed or were uncertain, and the manager will not make a late buy. The manager used various sources, including investor websites and news articles, to gather information. The manager also noted that crypto macro dates alone do not provide enough information to identify a trading opportunity, and no token event or tradable price edge has been established. The manager concluded that calendar verification is necessary but not enough, and eligibility, foreign exchange, and payoff are uncertain for foreign companies. The manager also noted that passed windows cannot be moved. As a result, the manager decided to allocate zero funds and preserve outcome monitors and collectors. No separate book is proposed because there is no independently demonstrated outside-mandate operation.

A scheduled repair for PRE91108 has been verified. The final list of jobs showed that 223 out of 224 executions were completed at 08:15:37 UTC, with a successful exit and final completion. This confirmation replaces the pending server verification from 2734, and the local success was also confirmed by the actual venue output. All five original source-collection workflows are still active, with identifiers 126, 132, 172, 223, and 224, and no trading instructions were given. A compact preview provides visibility into completion and errors, but does not retain full documents or economic data. The next runs are scheduled for 10:15 UTC for 223 and 16:15 UTC for 224, and the next manager run is at 12:30 UTC. The source of this information is the list_jobs function for the catalyst fund, which recorded actual receipt observations during this run.

The fund started with $49.14 in cash and $850.99 in the account, with no holdings or pending orders. The goal is to make a profit before the first news event, with the constraint that the payoff must be eligible and executable, and not result in a monthly shortfall of $349.01. The premises for this decision are: 1) recent FDA and call events make it difficult to enter the market in the usual way; 2) studies of past events have not provided conclusive results; 3) the stress on the market's range is negative after accounting for costs; and 4) recent primary results have changed the market's context, but are not a reason to enter the market now. The conclusion is to preserve the $49.14 in cash and not place any orders. This decision is based on unmet timing and payoff requirements, and is limited to the reviewed candidates and studies. The strongest argument against this decision is the positive trend of HITI and potential cash-driven reratings, but this is not enough to justify buying outside the tested window. The allocation is set to 0, and a new measured edge with a verified date would change this decision. Monitors and jobs will preserve follow-up. The sources for this decision include issuer dates, stock bar data, and press releases from Oracle and SEC filings.

A news scan found the following text: 1. list_jobs and saved notes confirm that 126, 132, and 172 have final END markers. Old 205 and 209 exit0 outputs truncate before completion, so exit code alone is insufficient. 2. Preserved original source scripts, wrapped every print in bounded panel receipts with length, hash, and preview error summaries, which is a way to track and verify the output. Local plain and final losslessly packed variants executed successfully: 7 print panels for 205, 11 for 209; both actual END observed, output less than 2200 characters. 3. Initial scheduling failed due to a 4000-character schema, which is a set of rules for organizing data; compressed 2845 and 3049 character variants preserve identical decoded logic. Originals cancelled, replacements submitted on same 120 and 480 minute cadence and 45 and 62 remaining runs. Full raw content exists only inside each sandbox; saved receipts deliberately use previews and never substitute for reading originals. Conclusion: collection completion is auditable; server first-run output remains to be checked at next run. Preserve source and branch manifests in list_jobs cancelled 205 and 209 and note 2305; no sixth collector, no economic conclusion from hashes. Sources include: list_jobs, query_research, and scripts pre91108/collector205.sh and collector209.sh.

The fund starts with $49.14 in cash and no holdings or orders. On Friday, September 11, there are calls for KR and HOFT, but the exact time of the first news is not given. There is also a PDUFA date for TLX Pixclara, which may bring early news. On this day, there will be releases of CPI and real earnings at 8:30 ET, Michigan preliminary sentiment and Census formations at 10:00 ET, and the Fed Z1 at noon ET. On Monday, September 14, HAIN will report before the open and HITI and PLAY will report after the close. The default exit for prior-session positions is set for today. There is an issuer date for Smaregi4431 on September 14, but the hour, venue, and FX are not verified. The BLS and Census calendars show no entries for Monday, but the Fed has routine releases at 13:00 ET, 16:15 ET, and other times, so it is not possible to rule out macroeconomic news. The FDA general calendar is not available, so it is not possible to confirm exhaustive coverage. The existing broad census 2412 is being reused as context, not as a new full-market screen. Strong cash and clinical evidence can change research priorities, but weak or missing releases will retain cash or date uncertainty. Neither outcome can bypass the need for an independent net edge and pre-event exit. Crypto macro exposure alone is not enough to meet the mandate of a dated-company run-up. The sources used are listed, including the BLS, University of Michigan, Census, and Federal Reserve websites, as well as issuer URLs. No orders or stops are required while the fund is flat. The next manager update will be at 12:30 UTC.

The fund started with $49.14 in cash, $850.99 in the account, and no holdings or queued orders. The goal was to achieve a net dated run-up with an exit before the release. The binding constraint is executable expectancy, not a monthly shortfall of $349.01. There were several premises: (1) the issuer confirmed the September 29 AMC on September 8, with a default prior-session exit on September 28. (2) The primary T5/1 ADR stop/3 ADR target training had a return of -7.89871% for 2586, -26.57828% for 2587, and -28.60560% for 2589, with zero holdout wins. All tested training variants had negative compounded returns. (3) The actual 15-minute RTH audit had a return of -27.72355% for 2662, with a drawdown of 29.76090% and no +2R trigger. (4) The training half Kelly was 2658 = 0. (5) The fundamental analysis required an adjusted free cash flow of $2542.289 million to meet the $640 million FY midpoint. The conclusion is that there will be no orders or exit changes, and the allocation will be 0. The validity of this decision is based on unmet entry gates, and the soundness is bounded by the selected company, retrospective calendars, overlapping news, seven-event test, and assumed costs. The strongest countercase is the positive recent T3 returns and cash-led rerating. The decision to preserve research without selecting a rule by its test was made. Cash was chosen due to the negative expectancy of this setup, not because every catalyst lacks an edge. Existing branches will retain their date follow-up, and no duplicate monitor or job will be created. A named gap remains in receipt completeness. No separate FUND case was considered. Analyses, observations, code archive, and three lessons were recorded, and the process was finished around 06:18, within the planned 43 minutes and maximum 45 minutes. The sources used were https://ir.concentrix.com/news/news-details/2026/Concentrix-Schedules-Release-of-Third-Quarter-2026-Financial-Results-and-Investor-Conference-Call/default.aspx, https://runway.adityaperswal.workers.dev/data/stock-bars, and the fundamental issuer URL in 2659.

The fund started with $49.14 in cash and $850.99 in the account, with no holdings or pending orders. The goal was to make a decision based on the FDA and earnings run-up, with a plan to exit before the event. There was a binding constraint on the net executable event payoff due to uncertain overlapping CBP clearance, which was not a monthly shortfall. The premises were: 1) the exact FDA date of September 28 was verified by the issuer on May 14, and only the date was considered for early decisions; 2) the ITC lift published on September 4 superseded the partial suspension from May, and included a full LEO/CDO with an XL drug combination, but the legacy base was unaffected and not all cash was safe; 3) cash reconstruction showed $2,485 pre-WC burn and $3.889 million in the first half of the year, with significant potential claims; and 4) frozen momentum from 2477 to 2480 showed a train of -96.87% and a holdout of -52.21%, with a stress of -64.46% and a half Kelly of 0. This negative control was not a backtest of the FDA event. The conclusion was to make no order and not move any levels, as the candidate had no independent net asymmetric run-up edge. The validity was limited by unmet entry conditions, and the soundness was limited by missing current CBP/appeal outcomes and post-restriction paid reorders. A strong bull case could be made with a positive FDA outcome, cheap redesign, and legacy utilization, but this would not assign a trade probability from the clinical 65.5%. The sources stopped changing the core answer after the September 1 update, and the absence of new SEC information was not pending proof. The prior cash constraint view was strengthened by the actual enforcement update, not blanket bearishness. The existing monitor was replaced on September 25, and the tested collector preserved all coverage. The next check will be at 06 UTC, and the fund will preserve zero unless there is a new primary ruling. There is no separate FUND case, as there is no validated outside-mandate operation. The sources for this information include the SEC and federal register websites, as well as a stock bars dataset.

The NIGHT911 collector replacement has preserved coverage within the five-job cap. There are three premises for this update: (1) new primary dates for NEOV, TBN, and CNXC require repeat checks without automatic order, (2) Catalyst has five active jobs and a sixth scheduling attempt was rejected, and (3) a combined 3500-character script was completed locally at 02:22:23 UTC with END5, preserving SRRK, SCHL, and PRAX RSS and SRRK latest 8-K while adding NEOV public published posts, TBN calendar and RSS, and CNXC SEC. The conclusion is that cancelled67 was only cancelled after the combined local test passed, and then scheduled205 was scheduled at 120 minutes for 48 runs and 90 seconds. Acceptance is not the same as execution receipt. The new cadence is faster but has a shorter lifetime than the old 480-minute 74-runs cadence, and handoff must renew after four days if still needed. A positive date and cash update requires full original and independent costed validation, while an adverse, early, or missing update requires re-verification and cash update. No order has been authorized. There are some limitations to this update: the latest three SEC forms can omit older relevant 8-Ks, the absence of RSS is not evidence of pending status, and source errors print explicitly. The primary URLs for this update are https://neovolta.com/press-releases, https://www.tamboran.com/corporate-calendar/, https://ir.tamboran.com/news-events/press-releases/rss, https://data.sec.gov/submissions/CIK0001803599.json, and https://investors.scholarrock.com/rss/news-releases.xml.

The automated trading fund manager started with $49.14 in catalyst cash and $850.99 in the account, with no holdings or queued orders. The goal is to achieve asymmetric dated earnings or FDA run-up with an exit before the first news, which is a type of event that can impact stock prices, also known as a catalyst. A binding constraint, or a rule that must be followed, is to implement an event edge, not a monthly shortfall of $349.01. The premises, or assumptions, include a full universe calendar join of 13,176 listings, 227 leads, and 231 price vectors, which yielded 10 technical passes. There were 3,057 foreign listing rows recorded, but these are not independent companies. New issuer dates include TBN on September 25, USA, NEOV on September 23, AMC, and CNXC on September 29, AMC, which correct discovery errors. NUVL has a stale PDUFA, or a US Food and Drug Administration approval, that has already been approved or acquired, and TLX/SRRK has no early decision seen in RSS, or a type of news feed, but this is not proof that it is pending. TBN has a costed fixed T-5 study, which is a type of statistical analysis, with a mean of 10.34245% and a confidence interval of [-0.4535, 3.6226]. The selected small history, current first gas regime, and unvalidated intraday management mean paper only, with T-5 on September 18 not being used now. NEOV has signed input cells and a framework, but not firm 18GWh sales, and full May 14 cash old, the day before the call. CNXC has a GAAP margin of 3.9%, which is below the SMA20, or a type of moving average. The EPM paper, or a type of financial model, is unchanged, and the train is -6.55%. The conclusion is that there are no orders or exits moved, and cash is chosen for reviewed payoff and validation gaps, not proof that the whole market lacks an edge, or a competitive advantage. The training TBN has a half Kelly, which is a type of betting strategy, of 12.292 capital fraction, which is unstable with an N1 loss, and approved 0. There is a whole 39.33 share 4.622% account total loss, which is not a quarter probe, or a type of financial analysis. The validity, or accuracy, of the results is bounded by retrospective calendar, selected survivors, small N, missing paid cash, and execution. A countercase, or an alternative scenario, is that new productive capacity could drive a fat-tail rally, or a type of stock price increase, and preserve prospective paper and collect cash rather than move past test entry. The monitors 235/236 are resolved, and 249 TBN/250 NEOV with CNXC are armed, or ready to trade. The older EPM 168/TLX 193 is preserved, or kept. A new collector and shortened name were tested after 60 character validation reject, and the final note holds the job id and receipt. There is no FUND case, or a type of investment strategy, with no validated separate operation. The sources of the data include https://www.tamboran.com/corporate-calendar/, https://neovolta.com/blog/neovolta-q4-fy26-earnings-call-timing, https://ir.concentrix.com/news/news-details/2026/Concentrix-Schedules-Release-of-Third-Quarter-2026-Financial-Results-and-Investor-Conference-Call/default.aspx, https://runway.adityaperswal.workers.dev/data/stock-bars, https://telixpharma.com/feed/, and https://investors.scholarrock.com/rss/news-releases.xml. The gaps, or missing data, include INTG/ATLO/NEOG/CWBC/HCWC dates, foreign eligibility and primary coverage, BB release body, CPRT cash and agreement, ORCL and ADBE calls, NEOV history and current funding, TBN cash and early news vintages, and not called absence, or a lack of data.

A news scan found the headline 'NET911 eight overseas market screen and crypto mandate boundary'. A TradingView screen for earnings release dates between September 11 and October 16 returned 3057 listing rows from the UK, Germany, France, Sweden, Japan, Australia, Hong Kong, and Canada. The screen retrieved all 157 observation chunks, but these include duplicate companies due to cross-listings. The volume ranking is based on local shares and does not reflect cross-market liquidity ranking. The primary calendar includes H&M's nine-month report on September 24, KGF's half-year report on September 22, and Abivax's H1 report on September 21. Yahoo quotes show the following prices: H&M at 164.35 SEK, KGF at 288.4 GBp, ABVX at 100.3 EUR, Fast Retailing at 65600 JPY, ASKUL at 1197 JPY, and GSK at 1775.5 GBp. The chart's previous close is a 5-day reference and not guaranteed to be the prior close. The ETHACDC 186 summary from September 3 chooses Sepolia on October 6 and defers Hoodi, but this does not confirm the Ethereum mainnet date. The fund mandate does not include native crypto with no earnings or FDA events, and it rejects protocol-only rotation. The goal is a dated run-up with a binding constraint on net event edge and tradability, not geographic availability. Sources include TradingView and company websites.

A news scan found the headline 'NET911 broad US listing-calendar screen: 227 leads, 10 technical passes, date errors'. The screen started with 13,176 listings from the Nasdaq and other sources, including 7,502 non-ETF listings. Over five weeks, from September 14 to October 16, 227 dates were added to the calendar. The screening process checked every listing in the universe, but did not analyze prices or prove that excluded names lacked events. The process used something called SIP histories, which are records of stock prices, and added six contexts to 233 of these histories. It then filtered the results to include only stocks with at least 51 days of price history, a mean dollar volume of at least $1 million over 20 days, and a closing price above the 20- and 50-day simple moving averages, which are measures of a stock's average price over a certain period. This yielded 10 stocks: INTG, NEOV, HITI, TBN, EPM, ATLO, NEOG, CWBC, TLX, and HCWC. The top-returning stocks were INTG with a 9.96% return, NEOV with a 9.88% return, and HITI with a 9.87% return. However, there were date errors: CNXC's issuer confirmed a September 29 event, not September 24; TBN's corporate calendar showed a September 25 event, not September 24; and NEOV's issuer search showed a September 23 event, not October 5. INTG's date was not recovered, and ATLO, NEOG, CWBC, and HCWC remain estimates with no entry. HITI has an imminent event on September 14, and EPM has a -6.55% return. TLX has early FDA risk. CNXC is below its 20-day simple moving average, and ABVX is above its whole-share cap but in a downtrend. The conclusion is to start a new event study for TBN and recover NEOV's date, but not to place any orders based on the screen. The validity of the results is limited to the calendar coverage and current survivors, and third-party calendar errors can change the results. The sources used include Nasdaq's listed and other listed stocks, an earnings calendar, and various company websites.

A news scan found the headline about the final decision of the MID911 fund. The fund started with a cash position, with no open, pending, or closing trades, and a goal of achieving documented earnings and a run-up before an event, with a defensible return of at least 3 times the risk. The fund's constraint was validated based on net expectancy and gap-aware implementation, but not capital recovery. The fund's backtest results showed a training return of -6.5511%, a holdout return of +3.8230%, a maximum drawdown of 3.9565%, and a win rate of 66.667%. The fund also considered the results of another backtest, which showed a return of -51.8445% over a period of 109 trades. The fund decided not to re-run or re-tune the model without a new validity reason. A new range model was tested, but it was negative after costs, and the fund decided to preserve the original model. The fund also considered the upcoming earnings date of AutoZone, which was confirmed for September 22, and the potential for a fractional exit, but decided not to propose an instrument. The fund concluded that there were no orders or exit moves, and that cash was the chosen position because the reviewed candidates lacked a validated asymmetric payoff. The fund's validity was limited to the reviewed sources, and the soundness was not proven for the whole market. The fund also considered a countercase scenario, but required independent prospective evidence. The fund's risk fraction was approved at 0, and the monthly return was excluded. The fund's monitors were resolved, and the existing collectors were preserved. The fund identified several gaps in the data, including the full results of Copart, the incremental calls of Oracle and Adobe, and the historical dates of AutoZone. The sources of the data included the fund's research query, trades query, and several websites, including those of Evolution Petroleum, AutoZone, Telix Pharma, and the SEC.

The automated trading fund manager started with $49.14 in cash and no holdings or orders. The goal was to earn money from companies that would have good news, such as FDA approvals, and then sell before the event happened, with a payoff of at least three times the risk. However, the manager found that the original training data showed a loss of 6.551%, and the holdout data had a confidence interval of -1.779% to 3.065%, which did not meet the requirements. The manager also considered the earnings reports of companies like Oracle, Adobe, and Zumiez, but they did not provide enough information to make a decision. Additionally, the manager looked at the pipeline risks of companies like Telix and Scholar Rock, but they were not resolved. As a result, the manager decided not to place any orders and to keep the $49.14 in cash. The manager also corrected the Kelly unit labels, which are a measure of the optimal bet size, and found that the actual capital allocation used in the simulation was 12.761%, not the half-Kelly sizing that was previously thought. The manager approved an allocation of 0, and the account settings were updated to reflect the normal risk and convex risk, as well as the position cap and fund cap. The manager also preserved the next-day paper exit and five jobs. The sources used for this decision included research queries, trade queries, and news releases from various companies.

The automated trading fund manager made a decision on September 14 to retain the Catalyst cash and not make any trades because there were no eligible stocks with a run-up of 3R or more. The fund started with $49.14 in cash and no holdings or queued orders. The goal is to find stocks with dated events and exit before the event. A binding constraint was validated to ensure the net payoff was not a capital permission. The EPM 1928 model showed all 12 train cells were negative, with a preferred return of -6.551%. The 1940 CLI model showed a return of -51.8445%, which is not out of sample. A paper trade on September 19 at 18:18 added 0.854R, but it did not meet the outcome criteria. Another paper trade with a return of 3.89686 and a live return of 4.06372 wished for a 3R return, but it could not be changed into an arithmetic return. The LOVE stock was already reported, and after investing, there was a refund of $23.633 million, but the bridge is unknown. The TLX and SRRK stocks had date certainty, but it did not remove the early decision or full pipeline gaps. The conclusion was to make no orders and approve a half Kelly allocation of 0 versus a raw selected sample of 1276117927. A strong countercase showed that the EPM was affordable and the acquisition mix may create upside, but there was no defensible 3R target or odds in the record. The validity follows prerequisites, and the soundness is bounded to existing reviewed setups, but it does not claim all market opportunities are negative. There was no quantification of the current expected value or universal 0/3 win probability. A monthly shortfall of $349.01 was excluded. The normal risk was 25.5297, convex risk was 42.5495, and position cap was 212.7475, but the fund capital cap of $49.14 does not establish an edge. The issues from August 208 to 209 were resolved, and the issues from August 213 to 214 were armed at 21 UTC. The paper exit on September 14 was retained. There are 5 active jobs maintained, and no EPM collector is at the known cap. There are no holdings or exits to review. The sources of the information include news releases from Evolution Petroleum, Lovesac, and Telix Pharma, as well as queries from the runway database.

The Catalyst fund has $49.14 in cash and $850.99 in account equity. The goal is to make a profit from events with a specific date, by exiting before the event news is released. A key rule is that the investment must have a good potential payoff and a validated entry point. The fund's original test, called EPM backtest1928, lost 6.551% and did not meet the required criteria. The current mandate requires a return of at least 3R, which is not met by the old paper return of 1.5R. The fund also considered a raw half Kelly of 12.7612%, but this was not approved. Some companies, like LOVE, have already reported negative cash flow after investing, while others like TLX and SRRK have upcoming event dates that expose early binary risk without validated odds. As a result, no new orders will be placed and no existing positions will be exited. The strongest argument against this decision is that an affordable EPM and improving market trends could lead to profits. However, the prerequisites for this were not met. The fund's existing monitors, including 208 and 209 at 19:40 and 168 paper exits on September 14, do not require any action. The current risk level is 3%/5%, which supersedes the previous 1% notes for new trades. No new risk is needed. The decision is based on information from various sources, including news releases from Evolution Petroleum and SEC filings from LOVE, as well as updates on TLX and SRRK from their respective websites and internal research queries.

The fund manager started with $49.14 in cash and $850.99 in the account. The goal is to achieve repeatable returns before events happen. A key rule is that any decision must be based on independently validated information that gives the fund an edge. The manager considered four main points. Firstly, a training model called EPM showed a loss of 6.551% and failed to meet certain criteria, and a delayed paper at 16:16 showed a return of +0.62927%, but this was not a new validation event. Secondly, a company called LOVE released information before the market opened, which verified a cash refund, but showed a loss of $23.633 million and an unknown guidance bridge. Thirdly, a stock called TLX had negative momentum and no validated FDA cohort, and while the issuer's September 11 date was verified, the current decision was not established by a bounded RSS. Lastly, there were no supported orders that required new execution pricing, and delayed SIP data was only historical. Based on these points, the manager decided not to propose, exit, adjust, or fund anything, and approved a Kelly criterion of 0. The strongest argument against this decision was that buying whole shares of EPM could yield a small gain, but this did not meet the necessary cost and validation criteria. The manager reviewed existing backtests and simulations without rerunning or retuning them, and did not claim any new backtest results. Certain issues were resolved, and new ones were scheduled for September 14. A new collector schedule was rejected, and five manual checks were preserved. Lessons 669-671 were recorded, and sources included news releases from Evolution Petroleum, SEC filings from LOVE, and news from Telix Pharma, as well as data from a stock bars website and two queries from a runway website.

The automated trading fund manager has made a decision to retain all $49.14 in catalyst cash. The fund started with $49.14 in cash and $850.99 in equity, with the goal of making a repeatable profit before an event, while also considering a binding constraint that is independently validated and costed, known as an edge, which is a competitive advantage. The premises of this decision are as follows: the actual paper open was 3.73, but the 2246 RR 1.08023 failed, and the 1928 training was negative, with a confidence interval cross of 0.2, and the LOVE actual released, with refund adjustments, and a 12.414% opening decline, did not provide post-event odds. The 2248 prior guide treatment is still conditional. The TLX existing 2167 training was negative, and the FDA event cohort was unvalidated. On September 11, the monitor retained 193, but did not claim the current decision was verified. The fresh consolidated execution quote was unavailable, and only historical delayed SIP was available. There were no open, pending, or closing positions. The conclusion is that there is no proposal to exit, adjust, or fund, and the quarter Kelly 0 was approved. A strong countercase is that the whole EPM lot is cheap, with a positive holdout and new organic LOVE products that may pay, but neither repairs the necessary gates. The soundness is limited to the selected history and unknown public call, and does not make a universal claim of having an edge. A reused simulation from 1942 showed a 10-event path with a raw fraction of 0.063806, and a 95% confidence interval of 48.845875 to 49.856086, with a loss of 24.838%. The indicators show a 2172 TLX trend and correlation that is not FDA odds, and there is no completed new daily return that justifies a refit. The sources of this information include news releases from Evolution Petroleum and The Lovesac Company, as well as data from the Bureau of Labor Statistics and a stock bars dataset. The query trades show that 167 out of 192 trades were resolved, and 200 out of 201 new trades were made at 16:30, with 20 armed and none overdue. The existing 5 collectors continue, and there is no off-run tradable signal. The analyses from 2246 to 49, and lessons 657 to 59, show a shortfall of $349.01, which is excluded from sizing.

The fund started with $49.14 in cash and $850.99 in equity, with no holdings or queued orders. The goal is to achieve repeatable pre-event profit. A primary event date of September 11 does not fix unknown FDA odds. No early decision was found in a bounded issuer review, and a new Ga68 panel is not Pixclara. The LOVE07 ET was released, with a 21% refund supporting profit, but comparisons show a -1.9% return, excluding the refund, with a GM of 56% and H1 FCF of -$23.633 million. The pre-event window is complete. Audited tests failed due to training and uncertainty, and the current IEX is stale. No positions need to be exited or adjusted. The conclusion is that there is no need to propose, exit, adjust, or fund. The quarter Kelly is valid at 0. The validity is limited because necessary trade gates were not met, and the soundness is limited due to a small, selected history. A countercase with a positive TLX19 holdout and real LOVE cash potential upside warrants research, but not turnover. The source URLs are 22786-94, 22799, 22800, and 22801, with key information from https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ and https://investor.lovesac.com/news-events/press-releases/detail/167/the-lovesac-company-reports-second-quarter-fiscal-2027. The review is complete, with 22 out of 183 items reviewed, and the next review is scheduled for September 11 at 13:50. No new tests are needed, and existing evidence is retained. Five existing jobs and 20 monitors cover research, with no orders queued. Lessons 645-647 and a shortfall of $349.01 are excluded from risk.

The automated trading fund manager made a final decision before the market opened at 08UTC. The fund started with $49.14 in cash and $850.99 in equity, which is a flat position. The goal is to repeat pre-event gains. The manager considered the primary calendar and cash bridge. The premises include verifying 9 earnings rows and checking the TLX stock on September 11, as well as the PPI and CPI, but this is not guaranteed to be the first news. The manager also considered a momentum train for TLX, which had a 25.273% loss and an 11.035% holdout. The technical analysis showed a net risk-reward ratio of 0.90536, which is less than 1.5. The fundamental analysis included an operating cash flow of $23.036 million and a free cash flow of $8.248 million. The manager did not propose any changes to the fund and approved the Kelly criterion as valid. The decision was based on the lack of a necessary edge and execution gates, as well as limited soundness due to small sample size and coverage gaps. A news scan found the headline 'FDA accepts NDA for TLX101' on the Telix Pharma website. The manager also reviewed the H1 2026 Interim Report and the schedule for the Bureau of Labor Statistics. The sources used include the Telix Pharma website, the Bureau of Labor Statistics, and the stock bars data for TLX and SPY. The full readable pre-open plan was created locally and saved.

The automated trading fund manager rechecked the original premises on September 10 at 08 UTC, making observations from 21402 to 21415. This was not the first news, and there was no entry edge due to calendar certainty. The following events are scheduled: TLX has a PDUFA goal date on September 11 for Pixclara, with the possibility of an early decision. The latest news from the issuer, retrieved on September 10, shows a conference notice but no verified decision, with a link to https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/. On the macro calendar, retrieved on September 10, the following events are scheduled: on September 10, the August PPI at 08:30 ET, and on September 11, the August CPI and real earnings at 08:30 ET, with a link to https://www.bls.gov/schedule/2026/09_sched.htm. Additionally, on September 10, the July wholesale trade at 10 ET, and on September 11, the August business formation at 10 ET, with a link to https://www.census.gov/economic-indicators/calendar-listview.html. The weekly petroleum key tables will be released on September 10 at 12 ET, with a holiday delay, and a link to https://www.eia.gov/petroleum/supply/weekly/schedule.php. The ECB will have its day 2 on September 10, with a press conference at 14:15 CET and a press page print at 14:45 CET, with a link to https://www.ecb.europa.eu/press/press_conference/html/index.en.html. The fund manager will require a record of actual primary release and independent costed actual window edge for stronger organic cash, label, and activity. If the release is weak, early, delayed, or absent, the fund will retain cash and reverify. No automatic trade will be made on either branch. The search for FDA product panels on September 10 and 11 did not find any additional confirmations. Existing reviews, including 22/137 and 13/20/21/33, cover key reviews. The fund started with 49.14 cash, aiming for repeatable run-ups, with a validated edge as a binding constraint. Coverage is bounded, with smaller issuers and first news minutes being incomplete. Macro shocks affect discount rates and demand but do not calibrate individual stock returns. The DOL actual on September 10, Michigan date, ECB UTC mapping, and TSM August primary numbers remain named gaps, not guesses.